GLP-1 Access for PCOS: Coverage, Cost and the Compounding Problem

Does insurance actually cover Ozempic or Wegovy for PCOS?

A PCOS diagnosis code alone does not trigger coverage for semaglutide under any major US insurer, because PCOS is not the indication either brand is approved for. Semaglutide carries two separate FDA-approved uses sold under two brand names: Ozempic, approved for type 2 diabetes, and Wegovy, a higher dose approved for chronic weight management. Insurers write their coverage rules against those approved indications and the diagnosis codes attached to them — type 2 diabetes, or obesity plus a qualifying weight-related condition — not against PCOS’s underlying insulin resistance, however similar the biology looks on paper.

That gap shows up clearly in the coverage data. A 2025 policy analysis from the Institute for Clinical and Economic Review found that, as of a July 2024 survey, only 33% of US health plans and employers were providing coverage for obesity treatment, with another 19% considering it — figures that rose to 67% among a separate sample of 125 large employers surveyed that August. State Medicaid coverage was narrower still: only 13 state programs covered GLP-1s for obesity as of October 2024, and fewer than 1% of Affordable Care Act marketplace plan formularies included drugs approved solely for obesity. Medicare has never covered GLP-1 drugs for an obesity-only indication; a proposed federal rule to add that coverage starting in 2026 was not taken up.

Why doesn’t a PCOS diagnosis open coverage the way diabetes does?

The same molecule is priced and labelled differently depending on which indication it’s sold for, and that split — not a judgment about PCOS — is what drives the coverage gap. The same 2025 analysis reports that net pricing for the obesity-labelled brands, Wegovy and Zepbound, runs roughly 1.5 to 2.8 times higher than the diabetes-labelled brands built on the identical active ingredients, Ozempic and Mounjaro. Manufacturers hold device-patent protection on the injector pens averaging a projected 18.3 years, which delays lower-cost generic competition on either version.

Insurers respond to that price gap with utilization controls rather than a blanket refusal. Pharmacy benefit managers frequently require step therapy — trying a cheaper, earlier-generation weight-loss drug first — and prior authorization tied to a specific BMI threshold, commonly 35 or 40 depending on the plan. Some plans have moved to covering only a single GLP-1 brand company-wide to negotiate a larger rebate. None of these controls are PCOS-specific; they apply identically to anyone seeking the obesity indication, PCOS or not. A coexisting type 2 diabetes diagnosis, or a BMI and comorbidity profile that independently qualifies under a plan’s obesity criteria, is what moves a claim from denied to approved — not the PCOS diagnosis itself.

Is GLP-1 treatment available for PCOS on the NHS?

PCOS is not a listed qualifying condition in either UK national approval for these drugs, and access instead runs on the same BMI-and-comorbidity formula used for any other cause of excess weight. NICE technology appraisal TA875 recommends semaglutide (Wegovy) only for adults with a BMI of at least 35 alongside one weight-related comorbidity, or a BMI of 30.0–34.9 who meet separate criteria for referral to a specialist weight-management service — and only within that specialist service, for a maximum of two years. TA1026 sets a near-identical bar for tirzepatide, sold as Mounjaro for both the diabetes and the weight-management indication in the UK, unlike the split US branding into Mounjaro and Zepbound. Both appraisals lower the qualifying BMI threshold by around 2.5 kg/m² for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds, in line with the ethnicity-adjusted thresholds used across UK obesity guidance generally.

NHS England’s interim rollout of tirzepatide narrows this further with a specific comorbidity list: hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease and type 2 diabetes. PCOS does not appear on it. As the phased commissioning plan expanded, someone with a BMI of 40 or more and four of those five conditions became eligible first; a BMI of 35–39.9 with the same four conditions was scheduled to follow around June 2026; and a BMI of 40 or more with three conditions around March 2027.

A PCOS diagnosis, even with documented insulin resistance, does not by itself satisfy either pathway. What does is an independently qualifying BMI plus one of the named conditions above — a distinction worth raising directly with a GP rather than assuming a PCOS diagnosis is sufficient on its own.

What does a GLP-1 prescription actually cost, and where should you check the real number?

List prices exist and are publicly documented, but they are not what most people actually pay, and they are specific to one country at one point in time. NICE’s own cost-effectiveness modelling for semaglutide used a UK list price of £175.80 per pack for the 2.4 mg dose — the figure NICE itself worked from in 2023 — but the NHS negotiates a separate, confidential discounted rate, and that list price has no bearing on what a US pharmacy, a private UK prescription, or a plan in another country charges. In the US, the 2025 policy analysis above put annual net commercial pricing in the $8,000–9,000 range against list prices several times higher, alongside a wide spread of prices reported across other high-income countries in the same period. None of these figures are stable enough to repeat as a current cost. The number that matters is whatever your own pharmacy, insurer or the NHS quotes you this month — check it there, not against any figure printed in an article.

What is compounded semaglutide, and why is it a genuinely different safety question?

Compounded semaglutide caused a documented cluster of 10-fold dosing errors, not a hypothetical risk. A case series reported to a regional poison control center described three patients who suffered adverse drug events after obtaining semaglutide from compounding pharmacies or a med spa; two of the three had self-administered roughly ten times the intended dose. All three had days of nausea, vomiting and abdominal pain, and one required IV fluids. This isn’t a labelling technicality — it is a mechanical consequence of how compounded product is dispensed.

Manufactured semaglutide and tirzepatide come in a pre-set injector pen that delivers a fixed, calibrated dose. Compounded versions are typically supplied as a vial that the patient draws up with their own syringe, converting milligrams into a volume in millilitres or “units” by hand — exactly the step where the poison-control cases went wrong. Compounding became widespread during a 2022–2025 manufacturing shortage of the approved products, when US regulation temporarily permitted it as a shortage workaround; as that shortage listing has since been lifted, the FDA has been narrowing the legal pathway that allowed most compounding pharmacies to keep producing it. Cost or coverage denial is a real reason people go looking for a cheaper source — but the dosing-error risk above is specific to the unregulated, syringe-based supply chain, not to the drug itself. A prescription for the manufactured product, dispensed with its calibrated pen, does not carry this particular risk. Deliberately taking less than that calibrated dose sits inside the same supply chain in most cases — why microdosing raises the same dosing risk is worth reading alongside the cost pressure driving the search for it.

You may see PCOS referred to as polyendocrine metabolic ovarian syndrome (PMOS), after a 2026 global consensus of more than 50 medical organisations renamed it. Nothing about how coverage or access decisions are made changes under either name — this article uses PCOS because that’s still what most readers search.

Where this doesn’t help

None of the coverage routes above open up because of a PCOS diagnosis by itself, so if your BMI sits below the qualifying threshold in your plan or country, or you don’t have one of the named comorbidities, this article can’t tell you a workaround — that’s a genuine access gap, not something a better appeal letter fixes. This page also doesn’t cover whether a GLP-1 is clinically appropriate for you: the trial evidence, contraindications and what happens after you stop are covered in full in GLP-1 drugs for PCOS, and are worth reading before an access conversation, not after. And if your main metabolic concern is fatty liver risk or central fat distribution rather than a GLP-1 specifically, PCOS and fatty liver and waist-to-hip ratio in PCOS cover the screening and measurement side of the same metabolic picture.

Your next step

Before contacting your insurer or GP, write down three things: your current BMI, any diagnosed weight-related condition beyond PCOS (blood pressure, sleep apnoea, cardiovascular disease, prediabetes or type 2 diabetes), and whether you’ve already tried metformin — the more established first step for PCOS’s insulin resistance, and one many plans expect as prior step therapy. Bring that list to the conversation instead of asking generally whether a GLP-1 is covered “for PCOS” — the answer depends on which of those boxes you can check, not on the diagnosis code alone. This article is one entry in this site’s weight-loss guide, which treats access and cost as metabolic-care logistics, not as a verdict on the person trying to navigate them.